Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
- Submitting institution
-
University of Exeter
- Unit of assessment
- 2 - Public Health, Health Services and Primary Care
- Output identifier
- 5615
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(19)30506-6
- Title of journal
- The Lancet Oncology
- Article number
- -
- First page
- 1760
- Volume
- 20
- Issue
- 12
- ISSN
- 1470-2045
- Open access status
- Compliant
- Month of publication
- October
- Year of publication
- 2019
- URL
-
-
- Supplementary information
-
https://ars.els-cdn.com/content/image/1-s2.0-S1470204519305066-mmc1.pdf
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
25
- Research group(s)
-
C - Health Service Research
- Citation count
- 26
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author, CTH, made a substantial contribution to the conception and design of the study; the organisation of the conduct of the study and to carrying out the study. CTH helped critique the output for important intellectual content. CTH led the health economics work stream following move of the lead health economist to Canada early in the project.
- Non-English
- No
- English abstract
- -